Pacifica Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

Pacifica Partners’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,200	Closed	-$10.4K	–	502
2025 Q2	$10.4K	Buy	+1,200	New	+$9.62K	﹤0.01%	333
2024 Q2	–	Sell	-1,000	Closed	-$4.99K	–	533
2024 Q1	$4.99K	Hold	1,000	–	–	﹤0.01%	409
2023 Q4	$8.81K	Hold	1,000	–	–	﹤0.01%	381
2023 Q3	$7.27K	Hold	1,000	–	–	﹤0.01%	383
2023 Q2	$9.94K	Hold	1,000	–	–	0.01%	298
2023 Q1	$9.82K	Hold	1,000	–	–	0.01%	312
2022 Q4	$4.11K	Hold	1,000	–	–	﹤0.01%	369
2022 Q3	$7K	Hold	1,000	–	–	0.01%	325
2022 Q2	$10K	Buy	+1,000	New	+$11.2K	0.01%	297
2021 Q4	–	Sell	-300	Closed	-$7K	–	479
2021 Q3	$7K	Sell	300 -3,650	-92%	-$57.9K	0.01%	325
2021 Q2	$50K	Buy	3,950 +300	+8%	+$3.82K	0.04%	151
2021 Q1	$47K	Buy	3,650 +1,000	+38%	+$14.5K	0.04%	147
2020 Q4	$35K	Hold	2,650	–	–	0.03%	149
2020 Q3	$39K	Hold	2,650	–	–	0.04%	133
2020 Q2	$40K	Hold	2,650	–	–	0.04%	131
2020 Q1	$38K	Buy	2,650 +625	+31%	+$11K	0.05%	135
2019 Q4	$41K	Buy	+2,025	New	+$18.7K	0.04%	148

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Pacifica Partners's AUPH Position: Q3 2025 in Review

Pacifica Partners sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2025, closing a stake of 1,200 shares — an estimated $10.4K sold.

Pacifica Partners first reported a position in AUPH in Q4 2019 and held it in 17 quarters. The position peaked at $50K in Q2 2021. 242 funds tracked by Wall St. Rank hold AUPH as of Q3 2025.

Pacifica Partners reported no remaining Aurinia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Pacifica Partners sold 1,200 Aurinia Pharmaceuticals shares in Q3 2025, an estimated $10.4K.
Pacifica Partners first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 17 quarters.
Pacifica Partners's Aurinia Pharmaceuticals position peaked at $50K in Q2 2021.
242 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2025.

Based on Pacifica Partners's 13F filing for Q3 2025, filed 9 Oct 2025.